MayoComplete Liquid Biopsy Panel, Next-Generation Sequencing, Cell-Free DNA
Use
This test is useful as an alternative to invasive tissue biopsies to assist in tumor profiling for diagnosis, predicting prognosis, and identifying targeted therapies for the treatment and management of patients with solid tumors. It also serves to assess microsatellite instability status, providing critical information that can guide immunotherapy decisions.
Special Instructions
This test is not a prenatal screening test. It requires a completed oncology request form or similar document indicating cancer diagnosis to aid in interpretation, although testing may proceed without it.
Limitations
The test does not differentiate between somatic and germline alterations, so additional testing may be necessary for clarification of the nature of detected alterations. It does not detect deletions and cannot assess all gene regions due to technical limitations such as regions of homology and high GC content. Rare alterations could lead to false negative or false positive results.
Methodology
NGS (Targeted)
Biomarkers
LOINC Codes
- 73977-1
- 50397-9
- 82939-0
- 69047-9
- 48767-8
- 31208-2
- 85069-3
- 62364-5
- 18771-6
- 42349-1
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
20 mL
Minimum Volume
10 mL
Container
Streck Cell-Free DNA blood collection kit
Collection Instructions
Collect whole blood in Streck Cell-Free DNA BCT tubes only. Process to produce platelet-poor plasma before cfDNA isolation.
Storage Instructions
Specimens should be transported at ambient or refrigerated (4 degrees C) temperature.
Causes for Rejection
Whole blood collected in tubes other than Streck Cell-Free DNA tubes
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |